Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.76 |
| ▸ | MEN1 | O00255 | 2/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.71 |
| ▸ | PDE4A | P27815 | 1/20 | 0.70 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.70 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.70 |
| ▸ | RELA | Q04206 | 1/20 | 0.68 |
| ▸ | P4HB | P07237 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.65 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL611778 | 1.00 | NR1H4 (1.00) | NR1H4ABCG2MEN1KMT2AABCB1 | |
| SCHEMBL29803121 | 1.00 | NR1H4 (1.00) | NR1H4ABCG2MEN1KMT2AABCB1 | |
| SCHEMBL11941382 | 0.88 | NR1H4 (0.79) | NR1H4ABCG2ABCB1P4HBCYP1A2 | |
| SCHEMBL25256717 | 0.87 | ABCG2 (0.78) | NR1H4ABCG2MEN1KMT2APDE4A | |
| SCHEMBL499524 | 0.86 | ABCG2 (1.00) | NR1H4ABCG2MEN1KMT2AABCB1 | |
| SCHEMBL20106717 | 0.86 | NR1H4 (0.76) | NR1H4ABCG2MEN1KMT2AABCB1 | |
| SCHEMBL14922407 | 0.86 | ABCG2 (1.00) | NR1H4ABCG2MEN1KMT2AABCB1 | |
| SCHEMBL29803073 | 0.86 | ABCG2 (1.00) | NR1H4ABCG2MEN1KMT2AABCB1 | |
| SCHEMBL10365559 | 0.86 | ABCG2 (0.85) | NR1H4ABCG2MEN1KMT2AABCB1 | |
| SCHEMBL3133053 | 0.86 | ABCG2 (0.85) | NR1H4ABCG2MEN1KMT2AABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12540144-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2026-02-03 | — | — | US | disclosed |
| US-20240239810-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2024-07-18 | — | — | US | disclosed |
| US-11945827-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-04-02 | — | — | US | disclosed |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-20220363692-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2022-11-17 | — | — | US | disclosed |
| EP-4037702-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | The Johns Hopkins University (US) | 2022-08-10 | — | — | EP | disclosed |
| CN-108904481-B | Application of o-hydroxy chalcone analogue in preparation of antioxidant drugs | 温州医科大学 | 2021-06-29 | — | — | CN | disclosed |
| WO-2021067439-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2021-04-01 | — | — | US | disclosed |
| CN-109265332-B | Polyhydroxy chalcone compound and application thereof | 北京理工大学 | 2020-11-13 | — | — | CN | disclosed |
| US-20030036654-A1 | Synthetic multimerizing agents | HOLT DENNIS A (US) | 2003-02-20 | — | — | US | disclosed |
| US-20020161240-A1 | Synthetic multimerizing agents | ARIAD GENE THERAPEUTICS, INC. | 2002-10-31 | — | — | US | disclosed |
| US-6150527-A | Synthetic multimerizing agents | ARIAD PHARMACEUTICALS, INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6133456-A | DIMERS OF THE MACROCYCLIC NATURAL PRODUCT, FK506, COVALENTLY ATTACHED TO EACH OTHER VIA A SYNTHETIC LINKER MOIETY | ARIAD GENE THERAPEUTICS, INC. (US) | 2000-10-17 | — | — | US | disclosed |
| EP-0888303-A1 | SYNTHETIC DERIVATIVES OF RAPAMYCIN AS MULTIMERIZING AGENTS FOR CHIMERIC PROTEINS WITH IMMUNOPHILIN-DERIVED DOMAINS | ARIAD GENE THERAPEUTICS, INC. (US) | 1999-01-07 | — | — | EP | disclosed |
| EP-0776327-A4 | NEW MULTIMERIZING AGENTS | ARIAD GENE THERAPEUTICS INC (US) | 1997-12-10 | — | — | EP | disclosed |
| WO-1997031899-A1 | SYNTHETIC DERIVATIVES OF RAPAMYCIN AS MULTIMERISING AGENTS FOR CHIMERIC PROTEINS WITH IMMUNOPHILIN DERIVED DOMAINS | ARIAD GENE THERAPEUTICS, INC. (US) | 1997-09-04 | — | — | WO | disclosed |
| WO-1997031898-A1 | SYNTHETIC DERIVATIVES OF RAPAMYCIN AS MULTIMERIZING AGENTS FOR CHIMERIC PROTEINS WITH IMMUNOPHILIN-DERIVED DOMAINS | ARIAD GENE THERAPEUTICS, INC. (US) | 1997-09-04 | — | — | WO | disclosed |
| EP-0776327-A1 | NEW MULTIMERIZING AGENTS | ARIAD GENE THERAPEUTICS, INC. (US) | 1997-06-04 | — | — | EP | disclosed |
| WO-1996006097-A1 | NEW MULTIMERIZING AGENTS | ARIAD GENE THERAPEUTICS, INC. (US) | 1996-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161240-A1 | Synthetic multimerizing agents | SSB, F13B, LCP2 | NR1H4 3357/4885ABCG2 3535/4885MEN1 547/4885 |
| US-20220363692-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | NR1H4 1419/4885ABCG2 2061/4885MEN1 3914/4885 |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | NR1H4 1419/4885ABCG2 2061/4885MEN1 3914/4885 |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | NR1H4 1419/4885ABCG2 2061/4885MEN1 3914/4885 |
| US-11945827-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, FKBP14, MTOR | NR1H4 1419/4885ABCG2 2061/4885MEN1 3914/4885 |
| US-12540144-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, CHP1, FKBP8 | NR1H4 275/4885ABCG2 1242/4885MEN1 4693/4885 |
| US-20030036654-A1 | Synthetic multimerizing agents | FKBP1B, FKBP2, FKBP14 | NR1H4 1495/4885ABCG2 1555/4885MEN1 1169/4885 |
| US-20240239810-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, MTOR, FKBP14 | NR1H4 1936/4885ABCG2 1922/4885MEN1 3911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.